RTCB and neoplasm: Further analysis from patient samples confirmed that protein aggregation could predict tumour sensitivity to therapy, as RtcB showed lower co-localisation with aggresomes in the metastatic versus primary tumours prior to antioestrogen treatment, confirming a role for RtcB in treatment resistance.